COMP <GO>
ANAB vs JNJ // EV/EBITDA & P/E VALUATION
AnaptysBio Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ANAB 4
— JNJ 5
▲ EV/EBITDA & P/E VALUATION LEADER: ANAB
LAST: $48.64 (-3.68%) • MKT CAP: $1.44B
valuation
5.7x
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANAB VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANAB | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 25.50% | +59.50 | ANAB | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 5.7x | 18.5x | -12.80 | ANAB | /valuation <GO> |
| Free Cash Flow Yield | 1.36% | 2.97% | -1.61 | JNJ | /fcf-yield <GO> |
| Operating Margin | 75.00% | 34.70% | +40.30 | ANAB | /operating-margins <GO> |
| Net Profit Margin | -5.60% | 28.50% | -34.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 157.00% | 6.00% | +151.00 | ANAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.59 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 62.1 | -15.36 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.44B | $662.49B | -$661.05B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANAB REV | JNJ REV | ANAB GROSS % | JNJ GROSS % | ANAB FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $234.6M | $94.19B | — | 67.9% | $19.6M | $19.70B |
| FY 2024 | $91.3M | $88.82B | — | 69.1% | -$135.7M | $19.84B |
| FY 2023 | $17.2M | $85.16B | — | — | -$120.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANAB // BETA —
JNJ // BETA 1.08